Scilex Holding (NASDAQ:SCLX) Shares Bought by Donald L. Hagan LLC

Donald L. Hagan LLC grew its holdings in Scilex Holding (NASDAQ:SCLX) by 32.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 173,292 shares of the company’s stock after buying an additional 42,500 shares during the period. Donald L. Hagan LLC’s holdings in Scilex were worth $74,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company acquired a new stake in shares of Scilex in the second quarter valued at approximately $25,000. Janus Henderson Group PLC increased its stake in Scilex by 3.5% during the 3rd quarter. Janus Henderson Group PLC now owns 534,302 shares of the company’s stock worth $494,000 after buying an additional 17,848 shares during the period. Finally, State Street Corp increased its stake in Scilex by 0.7% during the 3rd quarter. State Street Corp now owns 7,484,310 shares of the company’s stock worth $6,920,000 after buying an additional 54,404 shares during the period. 69.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SCLX has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Scilex in a report on Monday, October 21st. Alliance Global Partners initiated coverage on shares of Scilex in a research note on Wednesday, October 16th. They set a “buy” rating and a $14.00 target price for the company. Finally, D. Boral Capital initiated coverage on shares of Scilex in a research report on Monday. They issued a “buy” rating and a $22.00 price target for the company.

Scilex Trading Down 2.2 %

Scilex stock opened at $0.44 on Friday. The firm’s 50 day moving average price is $0.50 and its two-hundred day moving average price is $0.90. Scilex Holding has a twelve month low of $0.38 and a twelve month high of $2.63.

Scilex (NASDAQ:SCLX) last announced its quarterly earnings results on Friday, January 17th. The company reported ($0.18) EPS for the quarter. As a group, sell-side analysts expect that Scilex Holding will post -0.57 earnings per share for the current fiscal year.

Scilex Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.